Treatment Option for Chronic Lymphocytic Leukemia Tumors Via Chimeric Antigen Receptor Modified T Cells Therapy (CART-19)
Felicia Morrison MSN, MBA, RN

**Problem Statement**
- NCI estimates 18,960 new cases of CLL in 2016
- 4660 of these will die of disease
- Median survival 5 years
- Improved treatment options with sustained remissions are urgently needed

**Purpose**
The purpose of this poster presentation is to increase awareness of a new treatment options

**Goal**
Educate novice and new beginner oncology nurses on a new treatment option for CLL patients.

**Learning Objectives**
- Describe the role of CART-19 therapy in the care of CLL patients,
- identify eligibility criteria for CART-19 clinical trial,
- recognize possible side effects from CART-19 infusion,
- discuss nursing management and antidote for cytokine release syndrome (CRS),
- evaluate knowledge gained.

**Evaluation**
Designed to test knowledge, understanding, ability to manage, awareness, side effects, comfort level and antidote for patients undergoing CART-19 therapy
- Pre-test, followed by
- In Service, followed by
- Post test

**RESULTS**
Pretest proficiency 10%
Posttest proficiency 80%

**Reference**